Inspire Medical Systems, Inc.
Inspire Medical Systems develops and commercializes a minimally invasive neurostimulation therapy for obstructive sleep apnea. Its proprietary Inspire system senses breathing and delivers mild hypoglossal nerve stimulation to keep the airway open, and it is sold primarily to hospitals and ambulatory surgery centers in the U.S. with additional international distribution.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueImplantable neurostimulation systems used to treat moderate to severe OSA.
The newer platform launched in the U.S. to expand adoption and upgrade the installed base.
Sales through distributors in selected Asia-Pacific markets and other non-U.S. countries.
Customers
The company sells to hospitals and ambulatory surgery centers, which are the purchasing entities for the procedure, while physicians and sleep centers drive patient identification and adoption. Reimbursement from commercial insurers, Medicare, Medicare Advantage, and government programs is central to customer purchasing decisions because the therapy is typically used in reimbursed care pathways.
Primary purchasing customers that acquire the Inspire system for implantation procedures and need reimbursement support.
Clinical referral and procedure-driving users who identify eligible OSA patients and influence adoption.
Patients covered by insurers and Medicare who need positive coverage policies for treatment access.
Channel partners in Japan, Singapore, Hong Kong, Thailand, and other select markets that sell and promote the therapy locally.
Government healthcare channel that purchases under contract for eligible patients.
Strategy
The company is focused on expanding adoption of Inspire therapy through physician education, direct-to-consumer marketing, and broader reimbursement coverage. It is also investing in next-generation products, especially Inspire V, and in regulatory expansion to support growth in additional international markets.
A newer platform can refresh demand, support upgrades, and improve the product's competitive position.
Coverage policies are essential because treatment uptake depends on payor approval and patient affordability.
The business relies on referral-driven adoption and patient activation for procedure growth.
Non-U.S. markets are still small but offer long runway if approvals and reimbursement improve.
Geography
Q1/2026Revenue is heavily concentrated in the United States, which represented 95.6% of 2025 revenue, while all other countries contributed 4.4%. Outside the U.S., the company sells directly in select European markets and Japan, and through distributors in parts of Asia-Pacific, which makes international growth dependent on local regulatory approvals, reimbursement, and channel execution.
Share of the revenue the company reports by geography.
Risks
The company is highly dependent on a single product franchise, so adoption, reimbursement, and competitive pressure directly affect growth. It also faces execution risk from direct sales scaling, surgeon capacity constraints, cybersecurity exposure, and foreign market complexity, while emerging alternatives such as GLP-1 drugs and competing OSA devices could slow penetration.
- Product concentrationImpact: HighLikelihood: Medium
Nearly all revenue comes from one therapy platform, so any slowdown in adoption or product issues would affect results materially.
Exposure: Sales of Inspire system accounted for substantially all revenue
- Reimbursement and coverage riskImpact: HighLikelihood: Medium
The therapy depends on third-party payor approval, prior authorization, and coverage policy maintenance.
Exposure - Cybersecurity and IT disruptionImpact: HighLikelihood: Medium
Core functions such as manufacturing, distribution, and patient data handling rely on IT systems and third parties.
Exposure - Competitive substitutionImpact: MediumLikelihood: Medium
Alternative OSA treatments, including GLP-1 drugs and competing neurostimulation devices, may divert patients or physicians.
Exposure - Sales force and capacity constraintsImpact: MediumLikelihood: Medium
Growth depends on a large direct sales organization and enough trained surgeons to perform procedures.
Exposure: ENT surgeon capacity constraints and direct sales execution
- International regulatory and foreign exchange riskImpact: MediumLikelihood: Medium
Non-U.S. expansion requires approvals, local compliance, and exposure to currency and trade issues.
Exposure: Europe and Asia-Pacific markets
Accounting
Judgemental itemsProduct sales can shift between quarters depending on procedure volume and shipment timing.
Impact: Quarterly comparability and reported growth rates
A device company launching new products must manage inventory levels, tooling, and obsolescence risk.
Impact: Cost of goods sold and gross margin
The company uses equity awards and has recorded taxes on net share settlement activity.
Impact: Operating expenses, equity, and cash flow
Investment in next-generation manufacturing assets affects depreciation and asset carrying values.
Impact: Balance sheet and future cost structure
Similar listed companies
Publicly listed companies with a comparable business focus.
NeuroPace Inc
NPCE · Surgical & Medical Instruments & Apparatus
NeuroPace is a U.S.-based medical device company focused on epilepsy treatment through its implantable RNS System.
InspireMD, Inc.
NSPR · Surgical & Medical Instruments & Apparatus
Ispire Technology Inc.
ISPR · Cigarettes
Intuitive Surgical, Inc
ISRG · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Intuitive Surgical designs and sells robotic-assisted surgical systems and related instruments, accessories, software, and services used to perform minimally invasive procedures.
Globus Medical, Inc
GMED · Surgical & Medical Instruments & Apparatus
Globus Medical is a U.S.-based medical device company focused on musculoskeletal care, with products used in spine, orthopedic trauma, hip, knee, extremity and neurosurgical procedures.
RemSleep Holdings Inc.
RMSL · Services-Personal Services
Last updated: 24/09/2026